How a struggling biotech company became a university 'spin-in'

Emma Ulker
DOI: https://doi.org/10.1038/d41586-024-02627-8
IF: 64.8
2024-09-11
Nature
Abstract:Despite meeting a clinical and societal need for snakebite antivenom development, VenomAb folded after four years, propelling co-founder Andreas Laustsen-Kiel to a role that combines entrepreneurship and academia. Despite meeting a clinical and societal need for snakebite antivenom development, VenomAb folded after four years, propelling co-founder Andreas Laustsen-Kiel to a role that combines entrepreneurship and academia.
multidisciplinary sciences
What problem does this paper attempt to address?